SCHEMBL6822353

SCHEMBL6822353

COC(=O)N1CCN(c2ccn3nc(-c4ccccc4)c(-c4ccc(=O)n(C(C)C)n4)c3c2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 1/20 0.39
HSD17B10 Q99714 5/20 0.39
CYP3A4 P08684 4/20 0.39
USP2 O75604 2/20 0.39
MAPT P10636 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MAPK1 P28482 2/20 0.36
ALDH1A1 P00352 2/20 0.36
HPGD P15428 1/20 0.36
HIF1A Q16665 1/20 0.36
RUVBL1 Q9Y265 1/20 0.35
POLB P06746 1/20 0.35
MEN1 O00255 1/20 0.35
CYP2C19 P33261 1/20 0.35
KMT2A Q03164 1/20 0.35
PDK2 Q15119 1/20 0.35
SUV39H2 Q9H5I1 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CYP1A2 P05177 2/20 0.34
HRH3 Q9Y5N1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6822588 0.91 ADORA1 (0.41) ADORA1HSD17B10USP2SMN1; SMN2MAPK1
SCHEMBL6821519 0.91 CKS1B (0.43) ADORA1MAPTALDH1A1PDK2
SCHEMBL6822057 0.91 ADORA1 (0.41) ADORA1HSD17B10USP2SMN1; SMN2MAPK1
SCHEMBL6822350 0.89 ADORA1 (0.40) ADORA1HSD17B10USP2SMN1; SMN2MAPK1
SCHEMBL6822064 0.89 USP2 (0.42) ADORA1USP2SMN1; SMN2ALDH1A1POLB
SCHEMBL6822552 0.89 ADORA1 (0.40) ADORA1MAPTSMN1; SMN2RUVBL1MEN1
SCHEMBL6822496 0.87 ADORA1 (0.42) ADORA1MAPTHRH3
SCHEMBL6818814 0.86 ADORA1 (0.39) ADORA1HSD17B10USP2MAPTSMN1; SMN2
SCHEMBL6818717 0.85 GRIA1 (0.40) ADORA1HPGDRUVBL1HRH3
SCHEMBL6822097 0.84 ADORA1 (0.39) ADORA1MAPTMAPK1ALDH1A1RUVBL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed
EP-1313733-A1 PYRAZOLOPYRIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-05-28 EP disclosed
WO-2002018382-A1 PYRAZOLOPYRIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110763-A1 Pyrazolopyridine compound and pharmaceutical use thereof ADRB1, ADRA1D, ADRB3 ADORA1 22/4885HSD17B10 962/4885CYP3A4 494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.